Peptides for Fracture & Bone Healing: The Evidence, Ranked (2026)

Teriparatide is recombinant human PTH(1-34), the first bone-anabolic osteoporosis drug, FDA-approved as Forteo in 2002. It is the single best-evidenced peptide for bone. The mechanism is dose-timing-dependent: a once-daily pulse at the PTH1 receptor is net anabolic, driving cAMP/PKA and Wnt/β-catenin signaling, increasing osteoblast number and survival, and suppressing the formation-inhibitor sclerostin. Its Grade A proof is for osteoporosis fracture prevention. The pivotal Fracture Prevention Trial (n=1,637) cut new vertebral fractures from 14% on placebo to 5% (RR 0.35), and the head-to-head VERO trial showed 5.4% new vertebral fractures vs 12.0% for risedronate — the first proof an anabolic beats an antiresorptive on fracture endpoints. For acute fracture healing, the honest grade drops to B: off-label, teriparatide likely shortens time-to-union and aids callus, but a hip-fracture meta-analysis found no improvement in union rates at 3 or 6 months and no reduction in reoperation. It is not FDA-approved for fracture acceleration. It is also approved for male and glucocorticoid-induced osteoporosis, and the FDA removed the 2-year lifetime cap in November 2020.

Best for

Postmenopausal, male, or glucocorticoid-induced osteoporosis where an anabolic agent is indicated to reduce fracture risk

Pricing

Prescription (branded/biosimilar); varies by insurer/pharmacy

Source: Neer et al., NEJM 2001 — Fracture Prevention Trial

Abaloparatide is a synthetic 34-amino-acid analog of parathyroid hormone-related protein, PTHrP(1-34), and an RG-conformation-selective PTH1R agonist, FDA-approved as Tymlos in 2017. Its Grade A evidence, like teriparatide's, is for osteoporosis fracture prevention. The pivotal Phase 3 ACTIVE trial (n=2,463 postmenopausal women) showed roughly an 86% relative reduction in new vertebral fractures versus placebo, plus significant reductions in nonvertebral, clinical, and major osteoporotic fractures — with lower hypercalcemia than teriparatide (3.4% vs 6.4%). The ATOM trial (n=228 men) drove the December 2022 FDA expansion to men, with large BMD gains, though it was powered for BMD rather than fracture. ACTIVExtend confirmed gains are preserved or augmented when followed by alendronate. The honest counterpoint: claims that abaloparatide is dramatically superior to teriparatide are partly hype — dose-matched rodent studies often show parity, and head-to-head fracture superiority was limited to major osteoporotic fractures. Critically, for acute fracture healing specifically there is no dedicated human union-rate RCT for abaloparatide; its proven benefit, like teriparatide's, is prevention, not knitting a break faster.

Best for

Osteoporotic patients (women or men) needing an anabolic with strong vertebral-fracture reduction and less hypercalcemia than teriparatide

Pricing

Prescription (Tymlos); varies by insurer/pharmacy

Source: Miller et al., JAMA 2016 — ACTIVE trial

Calcitonin is a 32-amino-acid peptide hormone that directly inhibits osteoclastic resorption — it is antiresorptive, not anabolic — and has been FDA-approved since 1975. It earns inclusion because it has genuine human RCT data relevant to vertebral fracture, but its niche has shrunk dramatically. The PROOF trial reported roughly 36% fewer new vertebral fractures at 200 IU intranasal, and multiple RCTs support short-term analgesia for acute osteoporotic vertebral-fracture pain. However, it is substantially weaker than bisphosphonates, denosumab, or the PTH-class anabolics, and it has shown no demonstrated hip or non-vertebral fracture benefit. A major caveat drove its decline: a 21-RCT FDA meta-analysis found a higher malignancy rate with calcitonin (4.1% vs 2.9%), now a label warning, and the EMA de-recommended it for osteoporosis in 2012. Because of that, we grade its practical, endpoint-specific usefulness B rather than A despite the RCT base. Its modern role is narrow: a hypercalcemia bridge, Paget's disease second-line, and short-term acute vertebral-fracture analgesia — not first-line fracture prevention, and not a fracture-union accelerator.

Best for

Short-term acute vertebral-fracture pain relief or a hypercalcemia bridge, when first-line agents are unsuitable

Pricing

Prescription (Miacalcin); low-cost generic available

Source: Hamdy 2020, PMC7716677 — calcitonin review

BPC-157 is a synthetic 15-amino-acid body-protection-compound peptide marketed for tissue repair. Its bone data are real but entirely animal-stage, so its bone grade is C. The landmark study is Šebečić et al. (Bone, 1999): in rabbits with a surgically created 0.8 cm segmental osteoperiosteal radius defect, all saline controls showed incomplete healing at 6 weeks, while BPC-157 significantly improved radiographic, microdensitometric, and histomorphometric outcomes — corresponding to those seen with autologous bone-marrow and cortical-graft implantation. In rat models, BPC-157 improved tendon-to-bone healing that did not heal spontaneously and restored muscle-to-bone reattachment, and its angiogenic VEGFR2–Akt–eNOS mechanism is well characterized in animals. But the human evidence for bone is none: no completed human RCT exists for any indication, and the only published human data are tiny uncontrolled safety pilots such as an IV pilot with n=2. A first Phase 2 RCT is registered (hamstring strain, not bone) but not reporting. Every human bone-healing claim is extrapolation from animals. It is not FDA-approved, sits in a 2026 compounding gray zone, and is banned in sport at all times under WADA S0 with no Therapeutic Use Exemption.

Best for

Understanding the preclinical regenerative rationale only — not established human bone therapy

Pricing

Not FDA-approved; no legitimate compounded price

Source: Šebečić et al., Bone 1999 (PMID 10071911)

GHK-Cu is an endogenous copper-binding tripeptide (glycyl-L-histidyl-L-lysine:Cu2+). Its best human evidence is topical — diabetic-ulcer wound healing and cosmetic collagen — not bone, so for fracture and bone specifically it sits at Grade C. The biological rationale is genuinely strong: copper is an obligatory cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin into organized, mineralizable matrix, and copper deficiency is linked to osteoporosis and impaired bone development. In bone-tissue-engineering models, GHK-Cu-incorporated 3D silk scaffolds promoted vascularized bone regeneration, enhanced osteoblast differentiation, and polarized macrophages toward the pro-healing M2 phenotype, while copper-releasing scaffolds increased new bone volume and angiogenesis in rat calvarial defects. But those are scaffold and material studies in animals, not systemic-peptide fracture trials. The human evidence for bone is none: there is no controlled human trial of injected or systemic GHK-Cu for fracture healing, osteoporosis, or bone regeneration. Topical creams at roughly 0.05–2% are the only evidenced route, and that is for skin. Injectable GHK-Cu is not FDA-approved, is absolutely contraindicated in Wilson's disease and copper-handling disorders, and carries a theoretical copper-accumulation risk with chronic systemic use.

Best for

Appreciating the copper-cofactor bone rationale only — not a validated systemic bone therapy

Pricing

No FDA-approved injectable; topical cosmetic products vary

Source: Pickart & Margolina, Biomed Res Int 2015 — GHK-Cu mechanism